IP Library Granted Patent US 9,549,924
Granted Patent B2
US 9,549,924 · App. 14/922,373 · Granted Jan 24, 2017

Use of buprenorphine dimer in the treatment of peripheral neuropathic pain

Inventor: Nikhilesh Nihala Singh (Mill Valley, CA)
Assignee: ORPHOMED, INC.
A61K31/485A61K9/0019A61K31/137A61K31/167C07C217/64C07C217/70C07C233/25C07D489/02C07D489/08C07D489/12C07D519/00C07C2101/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,549,924
App. No.
14/922,373
Granted
Jan 24, 2017
Kind
B2
Abstract

The present invention provides method and compositions for the treatment of peripheral neuropathic pain by administering to a patient a therapeutically effective amount of a buprenorphine dimer compound, wherein the two buprenorphine portions are linked via an ethylene spacer, and wherein the spacer is bonded to the two opioid molecules via an ether bond. Preferably, the active agent is provided in the form of an injectable depot.

Claims (10)

1. A method of treating a patient suffering from peripheral neuropathic pain which comprises parenterally administering to said patient a therapeutically effective dose of a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and buprenorphine dimer compound having Formula (I):

or a pharmaceutically acceptable salt or solvate thereof.

2. The method according to method of claim 1 , wherein the dimer compound is in the form of a pharmaceutically acceptable salt.

3. The method of claim 1 wherein the composition is administered intramuscularly or subcutaneously.

4. The method of claim 1 wherein the compound is administered by subcutaneous depot injection.

5. The method of claim 1 , wherein the patient is a human and wherein the dose of dimer compound is administered is about 0.3 to about 1 mg.

6. The method of claim 4 wherein the dose of dimer compound is from about 5 to about 20 mgs.

7. The method of claim 4 wherein the dose of dimer compound is from about 20 to about 80 mgs.

8. The method of claim 4 wherein the patient suffered from diabetic neuropathic pain.

9. The method of claim 4 wherein the patient suffers from post herpetic neuropathic pain.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2023
From: ORPHOMED, INC.
To: DIMERX, INC.
Reel/Frame 063610/0911 →
SECURITY INTEREST Recorded Jun 11, 2021
From: ORPHOMED, INC.
To: COMERICA BANK
Reel/Frame 056508/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2016
From: SINGH, NIKHILESH NIHALA
To: ORPHOMED, INC.
Reel/Frame 038643/0828 →
Continuity (6)
Continuation In Part 14697155 · Apr 27, 2015
Continuation In Part 14697174 · Apr 27, 2015
Provisional Application 61985207 · Apr 28, 2014
Provisional Application 62101768 · Jan 9, 2015
Provisional Application 62176883 · Jan 9, 2015
Related Publication 20160038481A1 · Feb 11, 2016